Stay updated with breaking news from Cutaneous Lymphomas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, will host a...
NICE uphold appeal by Kyowa Kirin, for POTELIGEO in the treatment of those living with certain ultra-rare blood cancers The National Institute for Health and Care Excellence (NICE) has upheld an appeal
Patients treated with POTELIGEO? (mogamulizumab) with higher levels of abnormal T-cells in the blood reported higher quality of life, compared to vorinostat, new data analysis released today at the
Patients treated with POTELIGEO®▼ (mogamulizumab) with higher levels of abnormal T-cells in the blood reported higher quality of life, compared to vorinostat, new data analysis released today at the European Hematology Association meeting1GALASHIELS, Scotland--(BUSINESS WIRE)--Kyowa Kirin International PLC (Kyowa Ki...
Kyowa Kirin Responds to the National Institute for Health and Care Excellence (NICE) Decision to Not Provide People Living With Certain Rare Blood Cancers Access to POTELIGEO (mogamulizumab) two very rare forms of non-Hodgkin lymphoma will not have access to an innovative systemic treatment following NICE's decision to not recommend mogamulizumab for routine use in the NHS . Kyowa Kirin is disappointed by this decision but remains committed to finding a resolution with NICE. The National Institute for Health and Care Excellence (NICE) today published its final appraisal document (FAD) for PO...